ArticleBMC infectious diseases2025
Epidemiology of tuberculosis and HIV coinfection among inpatients in chengdu, china, 2018-2022.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Survival and risk factors of mortality among patients with TB/HIV coinfection in Kigali City, Rwanda: a retrospective cohort study (2019-2024).BMC infectious diseases · 2026Article
- Tuberculosis incidence trends and risk factors among people living with human immunodeficiency virus (HIV) in Sichuan, China: a retrospective cohort study (2010-2024).BMC infectious diseases · 2026Article
- A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2026 Update for Clinicians and Scientists.Pathogens & immunity · 2026Review
- A Diagnostic Puzzle: Unveiling Tuberculosis Peritonitis in an Immunocompromised Patient.Cureus · 2025Article
- CD4Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTuberculosis (TB) and human immunodeficiency virus (HIV) infection are infectious diseases that pose serious threats to human health. TB and HIV can interact to promote the progression of diseases. This study aims to provide basic evidence for the formulation of disease prevention and control strategies.
methodA retrospective study was conducted to analyze the characteristics of demographics and comorbidity, in an attempt to identify factors associated with HIV and TB coinfection among TB inpatients at Public Health Clinical Center of Chengdu, China from January 2018 to December 2022.
resultsAmong 37,587 TB inpatients, HIV-positive and HIV-negative TB cases accounted for 6.1% (2,301) and 93.9% (35,286), respectively.11.9% (4,468) were extrapulmonary tuberculosis (EPTB), of which 6.2%(278) were HIV-positive EPTB. Among TB, the most common types of HIV-positive TB were pulmonary tuberculosis (PTB) (87.9% [2,023]), tuberculous pleurisy (34.4% [791]), and lymph node tuberculosis (33.1% [762]). The proportion of HIV-positive TB decreased from 7.0% in 2018 to 5.1% in 2022 (P < 0.001), showing a downward trend. Factors associated with HIV-positive TB included being 18–59 years of age, male sex, divorced or widowed status, and urban residence. The comorbidity factors associated with HIV-positive TB included hepatitis C infection and syphilis. Those with HIV-positive TB were more likely to be complicated with opportunistic infections, including cryptococcal infection, toxoplasma infection, cytomegalovirus (CMV) infection, and Pneumocystis jirovecii pneumonia (PjP).
conclusionEarly screening for HIV in TB with associated factors, comprehensive management, and control of comorbidities may significantly contribute to achieving the WHO End TB Strategy targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.